Research Paper Volume 14, Issue 15 pp 6299—6315

Establishing and validating an ADCP-related prognostic signature in pancreatic ductal adenocarcinoma

class="figure-viewer-img"

Figure 10. (A) The mutational landscape of two immune subtypes (high risk and low risk) (B) The potential sensitive targeted drugs in high risk group and low risk group.